Download PDF
Semin Thromb Hemost 2022; 48(02): 219-228
DOI: 10.1055/s-0041-1736572
Review Article

Postpartum Hemorrhage in Patients with Type 1 von Willebrand Disease: A Systematic Review

Rebecca A.M. Pierce-Williams
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania
,
Mona M. Makhamreh
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania
2   Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn, New York
,
Sophia Blakey-Cheung
3   Department of Obstetrics and Gynecology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, South Shore University Hospital, Bay Shore, New York
,
Zimeng Gao
4   Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania
,
Huda B. Al-Kouatly
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Type 1 von Willebrand disease (VWD) is the most common subtype of VWD, comprising 75% of VWD patients. We provide a systematic review of type 1 VWD in pregnancy. Our objective was to evaluate the rate of postpartum hemorrhage (PPH) in patients with known type 1 VWD. The primary outcome was rate of PPH. Primary PPH was defined as a cumulative blood loss ≥1,000 mL, or blood loss accompanied by signs and symptoms of hypovolemia within 24 hours postpartum or requiring blood products. Secondary PPH was defined as significant bleeding 24 hours to 12 weeks postpartum. Relevant articles published in English pertaining to VWD and pregnancy were identified without any time or study limitations. Seven articles (n = 144 pregnancies) met inclusion criteria. The rate of primary PPH was 4/144 (2.8%). The secondary PPH rate was reported in four studies, and occurred in 7/48 pregnancies (14.6%), ranging from 2 to 19 days postpartum. In conclusion, according to this systematic review, the frequency of primary PPH in pregnancies with known type 1 VWD is 2.8%. This is similar to the overall PPH rates of 3% reported in the literature. Although the sample size was small, secondary PPH occurred in almost 15% of pregnancies, while in the overall obstetrical population this occurs in approximately 1% of cases. Patients with known type 1 VWD may not be at increased risk of primary PPH, though they appear to bear increased risk of secondary PPH.

Keywords

von Willebrand disease - type 1 VWD - postpartum hemorrhage - pregnancy

Supplementary Material



Publication History

Article published online:
08 November 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Castaman G, Linari S. Diagnosis and treatment of von Willebrand disease and rare bleeding disorders. J Clin Med 2017; 6 (04) E45
    CrossrefPubMedGoogle Scholar
  • 2 Sadler JE, Budde U, Eikenboom JCJ. et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
    CrossrefPubMedGoogle Scholar
  • 3 James PD, Connell NT, Ameer B. et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv 2021; 5 (01) 280-300
    CrossrefPubMedGoogle Scholar
  • 4 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69 (02) 454-459
    CrossrefPubMedGoogle Scholar
  • 5 Committee Opinion No. 580: von Willebrand disease in women. Obstet Gynecol 2013; 122 (06) 1368-1373
    CrossrefPubMedGoogle Scholar
  • 6 Castaman G. Changes of von Willebrand factor during pregnancy in women with and without von Willebrand disease. Mediterr J Hematol Infect Dis 2013; 5 (01) e2013052
    CrossrefPubMedGoogle Scholar
  • 7 Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet Gynecol 2017; 130 (04) e168-e186
    CrossrefPubMedGoogle Scholar
  • 8 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6 (07) e1000097
    CrossrefPubMedGoogle Scholar
  • 9 Castaman G, Tosetto A, Rodeghiero F. Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor mutations. Haematologica 2010; 95 (06) 963-969
    CrossrefPubMedGoogle Scholar
  • 10 Ramsahoye BH, Davies SV, Dasani H, Pearson JF. Obstetric management in von Willebrand's disease: a report of 24 pregnancies and a review of the literature. Haemophilia 1995; 1 (02) 140-144
    CrossrefPubMedGoogle Scholar
  • 11 James AH, Konkle BA, Kouides P. et al. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Haemophilia 2015; 21 (01) 81-87
    CrossrefPubMedGoogle Scholar
  • 12 Ito M, Yoshimura K, Toyoda N, Wada H. Pregnancy and delivery in patients with von Willebrand's disease. J Obstet Gynaecol Res 1997; 23 (01) 37-43
    CrossrefPubMedGoogle Scholar
  • 13 Sood SL, James AH, Ragni MV. et al. A prospective study of von Willebrand factor levels and bleeding in pregnant women with type 1 von Willebrand disease. Haemophilia 2016; 22 (06) e562-e564
    CrossrefPubMedGoogle Scholar
  • 14 Stoof SC, van Steenbergen HW, Zwagemaker A. et al. Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey. Haemophilia 2015; 21 (04) 505-512
    CrossrefPubMedGoogle Scholar
  • 15 Ragni MV, Machin N, James AH. et al. Feasibility of the von Willebrand disease PREVENT trial. Thromb Res 2017; 156: 8-13
    CrossrefPubMedGoogle Scholar
  • 16 Thomas KB, Sutor AH, Altinkaya N, Grohmann A, Zehenter A, Leititis JU. von Willebrand factor-collagen binding activity is increased in newborns and infants. Acta Paediatr 1995; 84 (06) 697-699
    CrossrefPubMedGoogle Scholar
  • 17 Callaghan WM, Kuklina EV, Berg CJ. Trends in postpartum hemorrhage: United States, 1994-2006. Am J Obstet Gynecol 2010; 202 (04) 353.e1-353.e6
    CrossrefPubMedGoogle Scholar
  • 18 Makhamreh MM, Kass SL, Russo ML, Ahmadzia H, Al-Kouatly HB. Type 3 von Willebrand disease in pregnancy: a systematic literature review. Am J Perinatol 2021; 38 (05) 436-448
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Makhamreh MM, Russo ML, Karl T. et al. Type 2B von Willebrand disease in pregnancy: a systematic literature review. Semin Thromb Hemost 2021; 47 (02) 201-216
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Reynen E, James P. Von Willebrand disease and pregnancy: a review of evidence and expert opinion. Semin Thromb Hemost 2016; 42 (07) 717-723
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Govorov I, Löfgren S, Chaireti R, Holmström M, Bremme K, Mints M. Postpartum hemorrhage in women with von Willebrand Disease—a retrospective observational study. PLoS One 2016; 11 (10) e0164683
    CrossrefPubMedGoogle Scholar
  • 22 Alexander J, Thomas P, Sanghera J. Treatments for secondary postpartum haemorrhage. Cochrane Database Syst Rev 2002; (01) CD002867
    PubMedGoogle Scholar
  • 23 Nichols WL, Hultin MB, James AH. et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (02) 171-232
    CrossrefPubMedGoogle Scholar
  • 24 Lee CA, Chi C, Pavord SR. et al; UK Haemophilia Centre Doctors' Organization. The obstetric and gynaecological management of women with inherited bleeding disorders—review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization. Haemophilia 2006; 12 (04) 301-336
    CrossrefPubMedGoogle Scholar
  • 25 WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 389 (10084): 2105-2116
    CrossrefPubMedGoogle Scholar
  • 26 ClinicalTrials.gov. US National Library of Medicine. Prevent Postpartum Hemorrhage in Women with von Willebrand Disease: the VWD-WOMAN Trial; 2020 April 4. NCT04344860 (in press). Hemophilia Center of Western PA: University of Pittsburgh
    PubMedGoogle Scholar
  • 27 Hawke L, Grabell J, Sim W. et al. Obstetric bleeding among women with inherited bleeding disorders: a retrospective study. Haemophilia 2016; 22 (06) 906-911
    CrossrefPubMedGoogle Scholar
  • 28 Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. Pregnancy in women with von Willebrand's disease or factor XI deficiency. Br J Obstet Gynaecol 1998; 105 (03) 314-321
    CrossrefPubMedGoogle Scholar
  • 29 Varughese J, Cohen AJ. Experience with epidural anaesthesia in pregnant women with von Willebrand disease. Haemophilia 2007; 13 (06) 730-733
    CrossrefPubMedGoogle Scholar
  • 30 Skeith L, Goodyear MD, Rydz N, Poon M-C. Epidural analgesia use in women with Von Willebrand disease. Blood 2014; 124 (21) 1529
    CrossrefPubMedGoogle Scholar